While Brexit negotiations continue,the UK remains a full and active member of the EU,with all the rights and obligations of EU membership firmly in place. But what will happen in the event of a‘no deal’ Brexit?
Following the outcome of the EU referendum, the Medicines and Healthcare products Regulatory Agency (MHRA) is working closely with the Government to analyse the best options and opportunities available for the safe and effective regulation of medicines and medical devices in the UK.
Playing a full, active role in European regulatory procedures for medicines remains a priority for the MHRA. It contributes significantly in both the centralised and decentralised regulatory procedures, including new rapporteur and reference member state (RMS) appointments, and maintaining its programmes for implementing EU legislation as required by its obligations as a Member State. The agency is also fully engaged in European and national scientific advice services and in delivering our EU inspection-related duties.
Devices regulation
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
